(Q40915887)

24 September 2017

1 reference

title

Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia (English)

1 reference

24 September 2017

1 reference

R Sheffield

1

1 reference

24 September 2017

S D Sullivan

series ordinal

2

1 reference

24 September 2017

E Saltiel

series ordinal

3

1 reference

24 September 2017

L Nishimura

series ordinal

4

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

Annals of Pharmacotherapy

24 September 2017

1 reference

24 September 2017

31

1 reference

24 September 2017

15-22

1 reference

24 September 2017

1

1 reference

Recombinant human erythropoietin for patients with AIDS treated with zidovudine

24 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Erythropoietin treatment of anemia associated with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Phase I-II Trial of Erythropoietin in the Treatment of Cisplatin-Associated Anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

The use of recombinant human erythropoietin to prevent carboplatin-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Chemotherapy of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Transfusion requirements, risks, and costs for patients with malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

The cost effectiveness of preoperative autologous blood donations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Comparisons of hospital care for patients with AIDS and other HIV-related conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Hepatitis B virus vaccine. Cost-benefit analysis of its use in a children's hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

The Declining Risk of Post-Transfusion Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery. A multicenter study of HIV-1 and HTLV-I/II infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

The low-incidence red cell antigen Wra: genetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Reports of 355 transfusion-associated deaths: 1976 through 1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Hepatitis C virus in a prospective study of posttransfusion non-A, non-B hepatitis in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

The distinction between cost and charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

Myelodysplastic (preleukemia) syndromes: the bone marrow factory failure problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703100101

10.1177/106002809703100101

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference